Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL

Kengo Kobayashi1, Kazuhito Yamashita, Hiromi Tasaki

  • 1The 2nd Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan.

Insights

Single low-density lipoprotein (LDL) apheresis significantly improves coronary flow velocity reserve (CFVR) in patients with familial hypercholesterolemia. This improvement is linked to decreased baseline flow velocity and favorable changes in plasma markers.

Area of Science:

  • Cardiology
  • Vascular Biology
  • Medical Technology

Background:

  • Lipid-lowering therapy can enhance endothelial function in coronary vessels.
  • Limited research exists on the impact of acute low-density lipoprotein (LDL) reduction on coronary flow velocity reserve (CFVR).

Purpose of the Study:

  • To determine if single low-density lipoprotein (LDL) apheresis improves coronary flow velocity reserve (CFVR) evaluated by adenosine 5'-triphosphate-induced hyperemia.
  • To investigate the effects of acute LDL reduction on coronary microvascular function.

Main Methods:

  • Seven patients with familial hypercholesterolemia and coronary stenosis were enrolled.
  • Coronary flow velocity reserve (CFVR) was assessed using transthoracic Doppler echocardiography (TTDE) before and after LDL apheresis.
  • Measurements included averaged diastolic peak velocity (ADPV) during hyperemia and plasma levels of bradykinin, 6 keto PGF1alpha, fibrinogen, and plasma viscosity.

Main Results:

  • Coronary flow velocity reserve (CFVR) increased significantly from 1.78 to 2.10 (P < 0.001) post-apheresis.
  • Averaged diastolic peak velocity (ADPV) at baseline decreased, suggesting vasodilation.
  • Plasma bradykinin and 6 keto PGF1alpha increased, while fibrinogen and plasma viscosity decreased.

Conclusions:

  • Single LDL apheresis enhances coronary flow velocity reserve (CFVR) in patients with familial hypercholesterolemia.
  • The improvement is attributed to decreased baseline flow velocity, likely due to epicardial artery dilation and improved microvessel function.
  • Changes in plasma LDL cholesterol, bradykinin, and PGI2 levels contribute to the observed vascular improvements.
Abstract